Skin test evaluation of a novel peptide carrier–based vaccine, BM32, in grass pollen–allergic patients

Míreanna Comhchosúla

• Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response
  le: Eckl-Dorna, Julia, et al.
  Foilsithe: (2019)
• Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
  le: Niederberger, Verena, et al.
  Foilsithe: (2018)
• Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines
  le: Weber, Milena, et al.
  Foilsithe: (2017)
• Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
  le: Focke-Tejkl, Margarete, et al.
  Foilsithe: (2015)
• Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection
  le: Cornelius, Carolin, et al.
  Foilsithe: (2016)